In this study, we evaluated both viral and host factors that have been shown to predict responses of CHC patients to pegIFNα and RBV combination therapy using the SCID/beige-Alb/uPA chimeric mouse model. The gene discussed is PLAU; the disease is cryohydrocytosis.